Aurobindo Pharma (AUROPHARMA) — Announcement

📢 Key Event
Aurobindo Pharma's US subsidiary Lannett launched generic Advair Diskus in the US market

💡 Investor Takeaway
This launch validates Aurobindo's inhalation expertise and adds a new revenue stream from complex US respiratory products.

Aurobindo Pharma announced that its US subsidiary Lannett Company LLC launched a generic version of GSK's Advair Diskus inhaler in the US market, marking the first product from Aurobindo's inhalation pipeline to reach US patients and expanding its complex inhalation portfolio.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AUROPHARMA ✨ Ask AI About This

About Aurobindo Pharma Ltd (AUROPHARMA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹96,836.1 Cr P/E: 26.3 ROE: 9.8% ROCE: 12.8% Div Yield: 0.24%

View full AUROPHARMA stock details →

📡 Get AI alerts when AUROPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AUROPHARMA — Free

💡 Ask AI about this filing

"When will revenue from Advair generic sales begin?" "How does this compare to competitors' generic Advair launches?" "What is the market share potential for this inhalation product in the US?"

Ask AI Free →

📊 More AUROPHARMA filings

See all AUROPHARMA filings →

🔥 Also filed on 31 August 2026

526159 Nikhil Adhesives Ltd Annual Report VIDHIING Vidhi Specialty Food Ingredients Ltd Annual Report 544855 Prima Innovation Ltd Annual Report TICL Twamev Construction & Infrastructure Ltd Annual Report TICL Twamev Construction & Infrastructure Ltd Annual Report TI Tilaknagar Industries Ltd Annual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AUROPHARMA files new disclosures

Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AUROPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd